Sangamo Therapeutics Inc (SGMO) VP Edward R. Conner Sells 5,000 Shares

Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $18.49, for a total transaction of $92,450.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Edward R. Conner also recently made the following trade(s):

  • On Monday, January 8th, Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $17.11, for a total transaction of $85,550.00.

Sangamo Therapeutics Inc (NASDAQ:SGMO) opened at $20.00 on Friday. The stock has a market cap of $1,867.91, a price-to-earnings ratio of -28.99 and a beta of 2.87. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. Sangamo Therapeutics Inc has a 1-year low of $3.60 and a 1-year high of $22.85.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.04. The company had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The company’s revenue for the quarter was up 333.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.27) earnings per share. research analysts predict that Sangamo Therapeutics Inc will post -0.73 EPS for the current fiscal year.

Several research analysts have commented on SGMO shares. Barclays started coverage on shares of Sangamo Therapeutics in a research report on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 price objective for the company. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, November 15th. Piper Jaffray Companies upgraded shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price objective for the company in a research report on Wednesday, November 15th. BidaskClub upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Finally, Wedbush restated a “hold” rating and set a $6.00 price objective on shares of Sangamo Therapeutics in a research report on Wednesday, November 15th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Sangamo Therapeutics currently has an average rating of “Buy” and a consensus price target of $18.83.

Several large investors have recently made changes to their positions in SGMO. Schwab Charles Investment Management Inc. increased its holdings in shares of Sangamo Therapeutics by 0.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock worth $2,353,000 after buying an additional 1,558 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Sangamo Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 339,842 shares of the biopharmaceutical company’s stock worth $2,990,000 after buying an additional 6,537 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Sangamo Therapeutics by 6.8% during the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 832 shares in the last quarter. Swiss National Bank increased its holdings in shares of Sangamo Therapeutics by 26.4% during the second quarter. Swiss National Bank now owns 143,560 shares of the biopharmaceutical company’s stock worth $1,263,000 after buying an additional 30,000 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Sangamo Therapeutics by 45.8% during the second quarter. Wells Fargo & Company MN now owns 431,234 shares of the biopharmaceutical company’s stock worth $3,795,000 after buying an additional 135,464 shares in the last quarter. Institutional investors own 64.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Sangamo Therapeutics Inc (SGMO) VP Edward R. Conner Sells 5,000 Shares” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://sportsperspectives.com/2018/02/09/sangamo-therapeutics-inc-sgmo-vp-edward-r-conner-sells-5000-shares.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply